53 related articles for article (PubMed ID: 17687168)
1. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
Martín G; Bellido L; Cruz JJ
J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
[No Abstract] [Full Text] [Related]
2. Neuro-ophthalmic complications of modern anti-cancer drugs.
Oskam JA; Danesh-Meyer HV
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; ():. PubMed ID: 38345654
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J; Dobariya P; Sharma SS; Pande AH
Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
[TBL] [Abstract][Full Text] [Related]
4. Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review.
Zou X; Zhou P; Lv W; Liu C; Liu J
Front Pharmacol; 2023; 14():1126235. PubMed ID: 36814495
[TBL] [Abstract][Full Text] [Related]
5. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma.
Tseng YJ; Chen CN; Hong RL; Kung WM; Huang AP
Brain Sci; 2022 Dec; 13(1):. PubMed ID: 36672016
[TBL] [Abstract][Full Text] [Related]
6. Posterior Reversible Encephalopathy Syndrome Associated with Oxaliplatin Use for Pancreatic Adenocarcinoma.
Symeonidis DG; Liatsos AD; Mazlimoglou EK; Geraki EC; Kosmas C
Case Rep Oncol; 2021; 14(2):838-844. PubMed ID: 34248548
[TBL] [Abstract][Full Text] [Related]
7. Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma.
Nakamura K; Saiki H; Muramatsu H; Morinaga S; Kobayashi I; Kajikawa K; Nishikawa G; Kato Y; Watanabe M; Kanao K; Sumitomo M
Int Cancer Conf J; 2017 Oct; 6(4):197-199. PubMed ID: 31149502
[TBL] [Abstract][Full Text] [Related]
8. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.
Chae YK; Chiec L; Adney SK; Waitzman J; Costa R; Carneiro B; Matsangou M; Agulnik M; Kopp P; Giles F
Oncotarget; 2018 Jun; 9(46):28281-28289. PubMed ID: 29963277
[TBL] [Abstract][Full Text] [Related]
9. Neurological complications of new chemotherapy agents.
Zukas AM; Schiff D
Neuro Oncol; 2018 Jan; 20(1):24-36. PubMed ID: 28992326
[TBL] [Abstract][Full Text] [Related]
10. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
Shah RR
Drug Saf; 2017 May; 40(5):373-386. PubMed ID: 28181126
[TBL] [Abstract][Full Text] [Related]
11. Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report.
Dos Reis Simões da Silva FM; Burgos Pêgo PM; Henriques Vendrell MC; de Azevedo Batalha Ferreira Dos Santos Farias MJ; Ribeiro Timóteo ÂC; Martins da Costa MC; Monteiro Barbosa Moreira Cravo IM; Ribeiro Gomes FM
Neuroophthalmology; 2011; 35(1):32-37. PubMed ID: 27956931
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice.
Dubois M; Le Joncour V; Tonon MC; Anouar Y; Proust F; Morin F; Gandolfo P; Joly F; Hilber P; Castel H
PLoS One; 2014; 9(12):e113533. PubMed ID: 25436776
[TBL] [Abstract][Full Text] [Related]
13. Guillain-Barré Syndrome following Treatment with Sunitinib Malate.
Kanaan Z; Kulairi Z; Titianu M; Saha S; Kumar S
Case Rep Oncol Med; 2014; 2014():712040. PubMed ID: 25018885
[TBL] [Abstract][Full Text] [Related]
14. Reversible posterior encephalopathy syndrome secondary to sunitinib.
Costa R; Costa R; Costa R; Junior GM; Cartaxo HQ; de Barros AC
Case Rep Oncol Med; 2014; 2014():952624. PubMed ID: 24900933
[TBL] [Abstract][Full Text] [Related]
15. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
Kim CA; Price-Hiller J; Chu QS; Tankel K; Hennig R; Sawyer MB; Spratlin JL
Invest New Drugs; 2014 Oct; 32(5):1036-45. PubMed ID: 24853074
[TBL] [Abstract][Full Text] [Related]
16. Posterior reversible leukoencephalopathy syndrome associated with pazopanib.
Foerster R; Welzel T; Debus J; Gruellich C; Jaeger D; Potthoff K
Case Rep Oncol; 2013 Jan; 6(1):204-8. PubMed ID: 23626562
[TBL] [Abstract][Full Text] [Related]
17. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
[TBL] [Abstract][Full Text] [Related]
18. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma.
Hadj JO; Braven RD; Tillier C; Schrijver HM; Verheul HM; VAN DER Vliet HJ
Oncol Lett; 2012 Jun; 3(6):1293-1296. PubMed ID: 22783436
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity of biologically targeted agents in pediatric cancer trials.
Wells EM; Nageswara Rao AA; Scafidi J; Packer RJ
Pediatr Neurol; 2012 Apr; 46(4):212-21. PubMed ID: 22490765
[TBL] [Abstract][Full Text] [Related]
20. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
Tlemsani C; Mir O; Boudou-Rouquette P; Huillard O; Maley K; Ropert S; Coriat R; Goldwasser F
Target Oncol; 2011 Dec; 6(4):253-8. PubMed ID: 22090260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
